The relevance of the use of mpMRI (multiparameter prostate magnetic resonance imaging) to evaluate the prostate in the context of PCa diagnosis lies in its ability to visualize primarily high-grade cancerous lesions that may be missed in routine diagnostic biopsies. standard. In several studies, mpMRI has shown improved performance compared to clinical models in identifying candidates who will benefit most from different therapies such as SA. Although data on mpMRI of the prostate during follow-up in men undergoing SA are sparse, there is potential to significantly improve AS programs through more accurate selection of optimal candidates which could achieve more accurate identification of progression of prostate cancer. disease and a reduction in the number of biopsies that would be needed to retest patients.
Buschke-Lowenstein tumor is a benign lesion of the skin and mucosa that occurs most commonly in the genital and perianal region of sexually active men and women. It is associated with human papillomavirus (HPV) and is treated with surgery in most cases. In addition, patients with immunodeficiency have a higher incidence of TBL. The initial clinical evaluation should include a detailed history, a careful physical examination, and an assessment of risk factors, including sexual activity, immunosuppression, and HPV exposure. The diagnosis of TBL is based on clinical presentation, histopathology and HPV detection. Histopathologic examination is necessary to confirm the diagnosis of TBL and to rule out other similar conditions. In addition, HPV detection is important to establish the risk of progression to malignant lesions and guide the management of TBL.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.